Price competition for Donepezil’s generics is high

The MOHW, Amendment to the Pharmaceutical reimbursement List

Eutropin lines, ‘price-volume aggreement+ expansion range' has been dropped

Pharmaceutical companies with Donepezil have lowered their reimubrsement premium caps and intensified price competition.

 

This time, drugs that voluntarily lowered were dropped from 36% to 67% below the current price.

 

This would be less than one-third of the highest price.

 

LG Chem's three lines of Eutropin are expected to be subject to additional drug price cuts due to the expanded range of use.

 

According to the industry on the 26th, the Ministry of Health and Welfare is pursuing the revision of the list of drug reimbursement and the cap.

 

When confirmed as scheduled, most will apply on the 5th of next month.

 

◆Lowered the upper limit due to price-volume aggreement negotiations= First of all, there are a total of eight drugs, which are priced in the price-volume agreement linkage and negotiated with the National Health Insurance Service.

 

Among the new drugs listed in the drug price negotiations, the same product group charges increased by more than 30% from the estimated bill at the time of negotiation.

 

Each falls by 2-3% from the current price.

 

In the case of Stivarga, the price dropped 3.2% from ₩378,18 to ₩36,608 from the 5th of next month, Lartruvo will be down 2.3% from ₩1,064,000 to ₩1,039,446 from February 1 2022.

 

Of the new drugs that have not been included in the 'Ka' group for four years, the total number of claims for the same product group has increased by more than 30%.

 

The new drug application date is the 5th of next month.

 

In other words, the total number of products cut by 'Na' group is six LG Chem's three Eutropin line items fell 6.1% each.

 

By item, Eutropin Plus 24mg will be cut from ₩172,626 to ₩162,096 , Eutropin will be reduced from ₩22,810 to ₩221,419, and Eutropin pen will be reduced from ₩202,060 to ₩189,734, respectively.

 

In particular, these products have extended their scope of use, resulting in advance drug price reductions based on the results of price-volume aggreement negotiations.

 

Trulicity 0.75ml by Lilly Korea, a genetically modified drug, has a 8.8% decrease from ₩21,722 to ₩10,981 and a Trulicity 1.5mg decrease from ₩34,289 to ₩38,014, down 9.8%.

 

Tresiva Flex Touch 100 units / ml by Korea's Novo Nordisk Pharm's fell 6.5% from ₩16,876 to ₩15,780.

 

◆Advance price reduction of extending the scope of use = There are a total of 15 products for which the pre-lower price for the expansion of the scope of use is effective on the 5th of next month.

 

In particular, LG Chem's Eutropin lines, which signed a price-volume aggreement, has expanded its scope of use and has been eligible for pre-price cuts.

 

In other words, the result is an additional 2.6% reduction in the price-volume aggreement negotiation.

 

By item, Eutrophin Plus 24mg ranges from ₩162,096 to ₩15,788,288, Eutrophin range from ₩21,419 to ₩28,620, and Eutropin pen range from ₩189,734 to ₩184,801.

 

Each is lowered.

 

Concerta OROS Tab lines by Jansen Korea also fell 1.5% each.

 

Concerta 18mg Tab will be lowered from ₩1,226 to ₩1,208, and Concerta 36mg Tab will be lowered from ₩1,849 to ₩1,821.

 

Lilly Korea, Strattera capsule line is also in ₩1,030 is by 3.6% lower to ₩993, Korea Pfizer, Genotropin 16IU to note to ₩89,530 from ₩91,920, as if notes Genotropin 12mg at ₩195,790, It drops 2.6% to ₩19,699 each.

 

◆Adjusted upper limit of voluntary price cut= 12 items have been lowered due to the drug maker's voluntary decision to lower its insurance price.

 

The government calculates and re-adjusts a manufacturer, a consigned manufacturer, or an importer to apply for a price cut at a price lower than the listed maximum drug price.

 

In general, it is a measure of cuts in line with its policies following market competition.

 

Prominent among these is the product of four donepezil preparations.

 

They decided to voluntarily cut from 31.6 percent to as high as 67.8 percent.

 

Considering that the highest drug content is ₩2,060, the price is lowered by a third or more.

 

Looking at the items, Hanpung Pharmaceutical's Doneil 5mg Tab voluntarily lowered from ₩2,060 to ₩675, and Doneil 10mg tab from ₩2,460 to ₩1,000.

 

They were reduced 67.2% and 59.3%, respectively.

 

Hwail Pharmaceutical's Donewon 5mg Tab decided to voluntarily cut from ₩980 to ₩670 and Donewon 10mg Tab from ₩1,480 to ₩950, 31.6% and 35.8%, respectively, were lowered by content.

 

In addition, Paroxat 20mg of Hallim Pharmaceuticals, will fall 23.4% from ₩560 to ₩690.

 

The Green Cross, Cansar 16mg tab will fall 16.3% from ₩824 to ₩690 , and the Cansarplus tablet will be reduced 15.6% from ₩853 to ₩720.